Vernakalant

Zusammenfassung

Vernakalant ist ein vielversprechendes neuartiges Antiarrhythmikum zur intravenösen Konversion von Vorhofflimmern in Sinusrhythmus. Es hemmt mehrere Ionenströme inklusive I_Kr und unterscheidet sich von herkömmlichen Antiarrhythmika durch eine relative Vorhofselektivität. Erreicht wird dies durch eine Hemmung des Kaliumstroms I_Kur, der nur im Vorhof vorkommt, und I_to, der aufgrund der kürzeren Aktionspotentiale eine relativ gesehen stärkere Auswirkung auf die Refraktärzeiten im Vorhof hat. Des Weiteren hemmt Vernakalant frequenz- und spannungsabhängig Natriumströme (I_Na). Die schnellen atrialen Aktionspotentiale bei Vorhofflimmern reagieren daher besonders gut auf Vernakalant, was sich klinisch in einer Konversionsrate von über 50 % bei weniger als 7 Tage bestehendem Vorhofflimmern zeigt. Eine Dosisanpassung von Vernakalant aufgrund von Alter, Geschlecht, Organinsuffizienzen oder Ko-Medikation scheint nicht erforderlich zu sein. Noch sind die Patientenzahlen in den durchgeführten Studien zu klein, um eine Aussage über das kardiale Nebenwirkungspotential von Vernakalant zu treffen. Die Kombination aus einem Trend zu Arrhythmogenität und noch geringer Erfahrung mit dieser neuen Substanz gebietet allerdings große Vorsicht auch nach Markteinführung.

Abstract

Vernakalant is a promising novel antiarrhythmic intravenous drug for the rapid conversion of atrial fibrillation to sinus rhythm. It blocks several ion currents important in cardiac action potential including IKr. Its difference to traditional antiarrhythmic drugs is a preferential effect on the atria, achieved by an inhibition of repolarizing potassium ion currents I_Kur, which is atrial-specific, and I_to, predominantly affecting atrial repolarization, as there is little atrial plateau potential. Furthermore vernakalant blocks frequency- and voltage-dependent sodium ion currents (I_Na). Thus rapid action potentials in atrial fibrillation are particularly targeted by vernakalant: this leads to a conversion rate to sinus rhythm in about 50 % of recent-onset attacks (less than 7 days) of atrial fibrillation. Age, gender, organ function and concomitant medication seem to have no clinically significant influence on the pharmacokinetics of vernakalant. The number of patients included in the studies is still too small to provide a definitive answer on its cardiac toxicity. However, a demonstrated tendency towards proarrhythmia and little experience with this new drug demands precaution even after it has been officially approved.

Vorhofflimmern - vorhofselektive Antiarrhythmika - ultraschneller verzögerter Gleichrichter - I_Kur - Vernakalant

atrial fibrillation - atrial selective antiarrhythmic drugs - ultrarapid delayed rectifier - I_Kur - Vernakalant

Literatur

• 1 Abi-Mansour P, Carberry P A, McCowan R J. et al . Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators.  Am Heart J. 1998;  136 632-642
• 2 AFFIRM First Antiarrhythmic Drug Substudy Investigators . Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug.  J Am Coll Cardiol. 2003;  42 20-29
• 3 Aktories K, Foerstermann U, Hofmann F, Starke K. Allgemeine und spezielle Pharmakologie und Toxikologie. 10th ed. München: Elsevier; 2009
• 4 Astellas Pharma US, Inc. Kynapid TM (vernakalant hydrochloride injection), new drug application (NDA) 22 – 034.  http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4327b1-01-astellas-backgrounder.pdf
• 5 Benjamin E J, Wolf P A, D’Agostino R B. et al . Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.  Circulation. 1998;  98 946-952
• 6 Cardiome Pharma Corp.  www.cardiome.com/VernakalantOral.php 2.7.2009
• 7 Chung M K, Martin D O, Sprecher D. et al . C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation.  Circulation. 2001;  104 2886-2891
• 8 Dessertenne F, Coumel P, Fabiato A. Ventricular fibrillation and torsades de pointes.  Cardiovasc Drugs Ther. 1990;  4 1177-1182
• 9 Dorian P, Pinter A, Mangat I. et al . The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans.  J Cardiovasc Pharmacol. 2007;  50 35-40
• 10 Ellenbogen K A, Stambler B S, Wood M A. et al . Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study.  J Am Coll Cardiol. 1996;  28 130-136
• 11 Fedida D, Orth P M, Chen J Y. et al . The mechanism of atrial antiarrhythmic action of RSD1235.  J Cardiovasc Electrophysiol. 2005;  16 1227-1238
• 12 Feinberg W M, Blackshear J L, Laupacis A, Kronmal R, Hart R G. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.  Arch Intern Med. 1995;  155 469-473
• 13 Fresco C, Proclemer A, Pavan A. et al . Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators.  Clin Cardiol. 1996;  19 409-412
• 14 Fuster V, Ryden L E, Cannom D S. et al . ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation).  J Am Coll Cardiol. 2006;  48 854-906
• 15 Goy J J, Kaufmann U, Kappenberger L, Sigwart U. Restoration of sinus rhythm with flecainide in patients with atrial fibrillation.  Am J Cardiol. 1988;  62 38D-40D
• 16 Healey J S, Morillo C A, Connolly S J. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.  Curr Opin Cardiol. 2005;  20 31-37
• 17 Hohnloser S H, Crijns H J, van Eickels M. et al . Effect of dronedarone on cardiovascular events in atrial fibrillation.  N Engl J Med. 2009;  360 668-678
• 18 Hohnloser S H, Kuck K H, Lilienthal J. Rhythm or rate control in atrial fibrillation – Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial.  Lancet. 2000;  356 1789-1794
• 19 Hume J R, Uehara A. Ionic basis of the different action potential configurations of single guinea-pig atrial and ventricular myocytes.  J Physiol. 1985;  368 525-544
• 20 Khan I A, Gowda R M. Novel therapeutics for treatment of long-QT syndrome and torsade de pointes.  Int J Cardiol. 2004;  95 1-6
• 21 Madrid A H, Moro C, Marin-Huerta E. et al . Comparison of flecainide and procainamide in cardioversion of atrial fibrillation.  Eur Heart J. 1993;  14 1127-1131
• 22 Mao Z L, Wheeler J J, Clohs L, Beatch G N, Keirns J. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.  J Clin Pharmacol. 2009;  49 17-29
• 23 Mays D J, Foose J M, Philipson L H, Tamkun M M. Localization of the Kv1.5 K+ channel protein in explanted cardiac tissue.  J Clin Invest. 1995;  96 282-292
• 24 McNamara R L, Tamariz L J, Segal J B, Bass E B. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography.  Ann Intern Med. 2003;  139 1018-1033
• 25 Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy.  Nat Rev Drug Discov. 2006;  5 1034-1049
• 26 Nattel S, Yue L, Wang Z. Cardiac ultrarapid delayed rectifiers: a novel potassium current family o f functional similarity and molecular diversity.  Cell Physiol Biochem. 1999;  9 217-226
• 27 Roy D, Pratt C M, Torp-Pedersen C. et al . Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.  Circulation. 2008;  117 1518-1525
• 28 Roy D, Rowe B H, Stiell I G. et al . A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.  J Am Coll Cardiol. 2004;  44 2355-2361
• 29 Roy D, Talajic M, Dorian P. et al . Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.  N Engl J Med. 2000;  342 913-920
• 30 Roy D, Talajic M, Nattel S. et al . Rhythm control versus rate control for atrial fibrillation and heart failure.  N Engl J Med. 2008;  358 2667-2677
• 31 Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches.  Europace. 2008;  10 647-665
• 32 Schmitt J, Ehrlich J R, Hohnloser S H. New antiarrhythmic drugs for the treatment of atrial fibrillation.  Herz. 2008;  33 562-567
• 33 Singh B N, Connolly S J, Crijns H J. et al . Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.  N Engl J Med. 2007;  357 987-999
• 34 Singh B N, Singh S N, Reda D J. et al . Amiodarone versus sotalol for atrial fibrillation.  N Engl J Med. 2005;  352 1861-1872
• 35 Slavik R S, Tisdale J E, Borzak S. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence.  Prog Cardiovasc Dis. 2001;  44 121-152
• 36 Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators.  Am J Cardiol. 1997;  79 418-423
• 37 The Cardiac Arrhythmia Suppression Trial (CAST) Investigators . Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.  N Engl J Med. 1989;  321 406-412
• 38 Trudeau M C, Warmke J W, Ganetzky B, Robertson G A. HERG, a human inward rectifier in the voltage-gated potassium channel family.  Science. 1995;  269 92-95
• 39 Van Gelder I C, Hagens V E, Bosker H A. et al . A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.  N Engl J Med. 2002;  347 1834-1840
• 40 Vernakalant: RSD 1235, RSD-1235, RSD1235.  Drugs R D. 2007;  8 259-265
• 41 Wang Z, Feng J, Shi H. et al . Potential molecular basis of different physiological properties of the transient outward K+ current in rabbit and human atrial myocytes.  Circ Res. 1999;  84 551-561
• 42 Wegener F T, Ehrlich J R, Hohnloser S H. Dronedarone: an emerging agent with rhythm- and rate-controlling effects.  J Cardiovasc Electrophysiol. 2006;  17 Suppl 2 S17-20
• 43 Wettwer E, Hala O, Christ T. et al . Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation.  Circulation. 2004;  110 2299-2306
• 44 Windle J R, Geletka R C, Moss A J, Zareba W, Atkins D L. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.  Ann Noninvasive Electrocardiol. 2001;  6 153-158
• 45 Wyse D G, Waldo A L, DiMarco J P. et al . A comparison of rate control and rhythm control in patients with atrial fibrillation.  N Engl J Med. 2002;  347 1825-1833